

PRIOR AUTHORIZATION POLICY

POLICY: Thrombocytopenia – Mulpleta Prior Authorization Policy

- Mulpleta® (lusutrombopag tablets – Shionogi/Quotient)

REVIEW DATE: 04/24/2024

OVERVIEW

Mulpleta, a thrombopoietin receptor agonist, is indicated for the treatment of **thrombocytopenia** in adults with **chronic liver disease** who are scheduled to undergo a procedure.¹

Begin Mulpleta treatment 8 to 14 days before the scheduled procedure. The recommended dose is 3 mg once daily with or without food for 7 days. In the pivotal clinical studies for the approved indication, patients had a platelet count $< 50 \times 10^9/L$.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Mulpleta. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Mulpleta is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Thrombocytopenia in a Patient with Chronic Liver Disease.** Approve for 7 days if the patient meets ALL of the following (A, B, and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has a current platelet count $< 50 \times 10^9/L$ ($< 50,000/mcL$); AND
 - C) Patient is scheduled to undergo a procedure within 8 to 14 days after starting Mulpleta therapy.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Mulpleta is not recommended in the following situations:

1. **Chronic Immune Thrombocytopenia.** Data are not available regarding use of Mulpleta in patients with persistent and chronic immune thrombocytopenia. Many other agents are FDA-approved for this condition and are recommended in standard guidelines and have established efficacy and safety.²
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

04/24/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

REFERENCES

1. Mulpleta® tablets [prescribing information]. Florham Park, NJ and Philadelphia, PA: Shionogi and Quotient; April 2020.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv.* 2019;3(23):3829-3866.